1. Scrip
  2. >>Therapy Areas

All Over For Asarina With No Partner Found For Tourette's Drug

Sepranolone may have progressed positively through a Phase IIa trial but its potential to reduce tics has failed to tempt any of the 20 or so potential partners that the Swedish biotech spoke to about a licensing deal.

Padlock
• Source: Shutterstock

The news that Asarina Pharma is going into liquidation is a disappointment both to the Swedish biotech's shareholders and to Tourette's syndrome patients hoping for safer and more effective therapies to come to market.

Asarina has discontinued development of its lead candidate, sepranolone, after conceding defeat in its bid to find a partner for the compound that modulates the effects of allopregnanolone, the neurosteroid implicated in the exacerbation of tics and other stress- and compulsion-related indications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.